[go: up one dir, main page]

MX2018003594A - Anticuerpo anti-garp. - Google Patents

Anticuerpo anti-garp.

Info

Publication number
MX2018003594A
MX2018003594A MX2018003594A MX2018003594A MX2018003594A MX 2018003594 A MX2018003594 A MX 2018003594A MX 2018003594 A MX2018003594 A MX 2018003594A MX 2018003594 A MX2018003594 A MX 2018003594A MX 2018003594 A MX2018003594 A MX 2018003594A
Authority
MX
Mexico
Prior art keywords
antibody
garp
tumor
treating
treg
Prior art date
Application number
MX2018003594A
Other languages
English (en)
Inventor
Satoh Kazuki
HIRAHARA Kazuki
Watanabe Ichiro
Amano Masato
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2018003594A publication Critical patent/MX2018003594A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con un anticuerpo que se une a GARP y es útil como agente terapéutico para un tumor, y un método para tratar un tumor usando el anticuerpo anteriormente mencionado. Un objeto de la presente invención es suministrar un anticuerpo, el cual inhibe la función de Treg en un tumor y de esta forma, es usado como producto farmacéutico que tiene efectos terapéuticos, un método para tratar un tumor usando el anticuerpo anteriormente mencionado, y similares. Se obtiene un anticuerpo anti-GARP que se une a GARP y exhibe actividad inhibidora a la función Treg y exhibe actividad ADCC, y además se obtiene una composición farmacéutica para uso en terapia de tumor, que comprende el anticuerpo anteriormente mencionado, etc.
MX2018003594A 2015-09-24 2016-09-23 Anticuerpo anti-garp. MX2018003594A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015187488 2015-09-24
PCT/JP2016/078067 WO2017051888A1 (ja) 2015-09-24 2016-09-23 抗ｇａｒｐ抗体

Publications (1)

Publication Number Publication Date
MX2018003594A true MX2018003594A (es) 2018-06-15

Family

ID=58386752

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003594A MX2018003594A (es) 2015-09-24 2016-09-23 Anticuerpo anti-garp.
MX2023003470A MX2023003470A (es) 2015-09-24 2018-03-22 Anticuerpo anti-garp.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023003470A MX2023003470A (es) 2015-09-24 2018-03-22 Anticuerpo anti-garp.

Country Status (28)

Country Link
US (4) US11046780B2 (es)
EP (3) EP3660051A1 (es)
JP (5) JP6878283B2 (es)
KR (2) KR102776730B1 (es)
CN (3) CN108026521B (es)
AU (3) AU2016325858B2 (es)
BR (1) BR112018005777A2 (es)
CA (1) CA2999819A1 (es)
CO (1) CO2018003542A2 (es)
DK (1) DK3354729T5 (es)
ES (1) ES2978126T3 (es)
FI (1) FI3354729T3 (es)
HR (1) HRP20240495T1 (es)
HU (1) HUE066594T2 (es)
IL (3) IL288784B2 (es)
LT (1) LT3354729T (es)
MX (2) MX2018003594A (es)
MY (1) MY194586A (es)
PH (1) PH12018500642A1 (es)
PL (1) PL3354729T3 (es)
PT (1) PT3354729T (es)
RS (1) RS65415B1 (es)
RU (2) RU2769379C2 (es)
SG (2) SG11201802352VA (es)
SI (1) SI3354729T1 (es)
SM (1) SMT202400160T1 (es)
TW (2) TWI836305B (es)
WO (1) WO2017051888A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035550B1 (ru) 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
ES2889906T3 (es) 2015-05-21 2022-01-14 Harpoon Therapeutics Inc Proteínas de unión triespecíficas y usos médicos
SG11201802352VA (en) * 2015-09-24 2018-04-27 Daiichi Sankyo Co Ltd Anti-garp antibody
CN109195990A (zh) * 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN119060177A (zh) 2016-05-20 2024-12-03 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
PE20200862A1 (es) 2017-12-12 2020-08-25 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados
TW202521585A (zh) * 2018-05-31 2025-06-01 日商第一三共股份有限公司 抗人類tlr7抗體、其用途及醫藥組成物
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN114630679A (zh) * 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
EP4255473A4 (en) * 2020-12-02 2025-02-19 Shanghai Henlius Biotech, Inc. Anti-garp/tgfbeta antibodies and methods of use
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
EP4277665A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
TW202241955A (zh) * 2021-01-18 2022-11-01 大陸商上海濟煜醫藥科技有限公司 Ｇａｒｐ蛋白抗體及其應用
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2024018046A1 (en) 2022-07-22 2024-01-25 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
DE69909459T2 (de) 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
RU2313368C2 (ru) 2001-11-01 2007-12-27 Ю Эй Би Рисерч Фаундейшн Комбинации антител, обладающих селективностью по отношению к рецептору лиганда, индуцирующему апоптоз, ассоциированный с фактором некроза опухоли, и других терапевтических средств
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
WO2006089678A2 (en) 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
US8815526B2 (en) 2005-03-31 2014-08-26 Case Western Reserve University Methods and reagents for identifying/isolating T regulatory (Treg) cells and for treating individuals
US20110086367A1 (en) 2006-04-03 2011-04-14 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
CN101679519A (zh) 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
AU2009203699A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
US8114968B2 (en) 2008-03-03 2012-02-14 Dyax Corp. Metalloproteinase-12 specific monoclonal antibody
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2010055950A1 (ja) 2008-11-17 2010-05-20 財団法人ヒューマンサイエンス振興財団 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
MX2011011825A (es) 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
CA2794196A1 (en) 2010-03-23 2011-09-29 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
MY158499A (en) 2010-10-29 2016-10-14 Daiichi Sankyo Co Ltd Anti-dr5 antibodies, polynucleotides and methods
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
PH12013502201A1 (en) 2011-04-25 2014-01-13 Daiichi Sankyo Co Ltd Anti-b7-h3 antibody
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JPWO2013147212A1 (ja) 2012-03-30 2015-12-14 第一三共株式会社 新規抗Ｓｉｇｌｅｃ−１５抗体
SG11201406422TA (en) 2012-04-09 2014-11-27 Daiichi Sankyo Co Ltd Anti-fgfr2 antibody
ES2733434T3 (es) 2012-04-27 2019-11-29 Daiichi Sankyo Co Ltd Anticuerpos anti-ROBO4
JP2014141434A (ja) * 2013-01-24 2014-08-07 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体
WO2013192504A1 (en) * 2012-06-22 2013-12-27 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
SG10201704616SA (en) * 2012-11-06 2017-07-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
EA035550B1 (ru) * 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
SG11201802352VA (en) * 2015-09-24 2018-04-27 Daiichi Sankyo Co Ltd Anti-garp antibody
CN109195990A (zh) * 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法

Also Published As

Publication number Publication date
CA2999819A1 (en) 2017-03-30
CN115869398B (zh) 2025-04-22
JP6868739B2 (ja) 2021-05-12
AU2020200866B2 (en) 2022-06-16
JP7137657B2 (ja) 2022-09-14
MY194586A (en) 2022-12-05
IL258322B1 (en) 2023-06-01
IL288784B1 (en) 2023-06-01
DK3354729T5 (da) 2024-09-30
FI3354729T3 (fi) 2024-04-23
DK3354729T3 (da) 2024-04-22
KR20250037587A (ko) 2025-03-17
HRP20240495T1 (hr) 2024-07-05
JP6878283B2 (ja) 2021-05-26
JP2021106617A (ja) 2021-07-29
RU2022108079A (ru) 2022-04-08
RS65415B1 (sr) 2024-05-31
IL258322A (en) 2018-05-31
TWI836305B (zh) 2024-03-21
AU2016325858B2 (en) 2022-05-26
EP3354729A1 (en) 2018-08-01
US10550198B2 (en) 2020-02-04
PT3354729T (pt) 2024-04-11
AU2022231706B2 (en) 2025-05-15
US20240360245A1 (en) 2024-10-31
RU2018114904A3 (es) 2020-03-03
JP2022169801A (ja) 2022-11-09
NZ780546A (en) 2025-05-30
EP4349997A2 (en) 2024-04-10
JP2020202875A (ja) 2020-12-24
RU2018114904A (ru) 2019-10-24
BR112018005777A2 (pt) 2018-10-09
SMT202400160T1 (it) 2024-05-14
MX2023003470A (es) 2023-04-19
LT3354729T (lt) 2024-04-25
IL258322B2 (en) 2023-10-01
AU2016325858A1 (en) 2018-04-19
IL302932B1 (en) 2026-01-01
EP4349997A3 (en) 2024-07-10
PH12018500642A1 (en) 2018-09-24
CN110922481A (zh) 2020-03-27
EP3354729B1 (en) 2024-02-14
HUE066594T2 (hu) 2024-08-28
AU2022231706A1 (en) 2022-10-06
KR20180053316A (ko) 2018-05-21
HK1254310A1 (en) 2019-07-19
CN115869398A (zh) 2023-03-31
IL288784B2 (en) 2023-10-01
TW202438526A (zh) 2024-10-01
WO2017051888A1 (ja) 2017-03-30
SG11201802352VA (en) 2018-04-27
KR102776730B1 (ko) 2025-03-05
EP3660051A1 (en) 2020-06-03
CO2018003542A2 (es) 2018-07-10
JPWO2017051888A1 (ja) 2018-07-12
RU2769379C2 (ru) 2022-03-30
IL302932A (en) 2023-07-01
CN108026521B (zh) 2022-12-06
ES2978126T3 (es) 2024-09-05
TW202227501A (zh) 2022-07-16
US12006372B2 (en) 2024-06-11
PL3354729T3 (pl) 2024-05-20
US11046780B2 (en) 2021-06-29
NZ741033A (en) 2025-05-30
AU2020200866A1 (en) 2020-02-27
SG10201912570UA (en) 2020-02-27
TWI751979B (zh) 2022-01-11
US20220010026A1 (en) 2022-01-13
US20180258184A1 (en) 2018-09-13
IL288784A (en) 2022-02-01
US20180327511A1 (en) 2018-11-15
SI3354729T1 (sl) 2024-05-31
JP2025036561A (ja) 2025-03-14
TW201718643A (zh) 2017-06-01
EP3354729A4 (en) 2019-06-12
CN108026521A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
PH12018500642A1 (en) Anti-garp antibody
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MY201148A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201591925A1 (ru) Терапевтические композиции и их применение
BR112018067923A2 (pt) métodos de tratamento de cânceres usando antagonistas de ligação de eixo pd-1 e anticorpos anti-gpc3
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
MX394452B (es) Inhibicion de la actividad de olig2.
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
BR112016023011A2 (pt) tratamento de câncer gástrico
MX394015B (es) Inhibición de la actividad de la olig2.
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
BR112017019816A2 (pt) compostos, composição farmacêutica, método para o tratamento profilático ou terapêutico de doença dos rins e/ou fígado em um sujeito, e uso de um composto
MA40363A (fr) Agents de liaison de rspo1 et leurs utilisations